Current Edition

CAR T

Gilead’s Kite flies higher as Yescarta leads CAR-T therapy class to earlier lymphoma treatment

Existing CAR-T therapies have been saved for blood cancer patients who’ve tried multiple treatments—until now. With a first-in-class nod, the FDA has cleared Yescarta, a …

Continue Reading →
bladder

That key Gilead breast cancer readout? Try 2024, and don’t get your hopes up: analyst

Gilead Sciences just tipped off what sounded like mixed results for Trodelvy, the cornerstone of the Big Biotech’s oncology ambitions. Now, one analyst suggests investors …

Continue Reading →
breast

Gilead drops unclear win for key Trodelvy breast cancer trial, poking holes in CEO’s oncology plan

Gilead Sciences has a lot of its oncology ambitions riding on Trodelvy’s success beyond its existing approvals. While investors have been waiting with bated breath …

Continue Reading →